First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting II Free access Breast Cancer—Metastatic June 04, 2025 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast0

First Posted 2022-11-21 Trial status Recruiting Sponsor Gilead Sciences Abstract Presentation Peer-reviewed journal publication Press Release FDA NCCN NCT05633654: Phase 3: (ASCENT-05/​AFT-65 OptimICE-RD/​GBG 119/​NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Hav

First Posted 2017-01-30 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation 2019 San Antonio Breast Cancer Symposium. Abstract GS3-03. Presented December 12, 2019. Schmid P, Park YH, Ferreira M, et al: KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatm